Skip to main content
. 2017 Apr 11;8(41):71164–71172. doi: 10.18632/oncotarget.17029

Table 1. Summary of cost ($) and outcome results from a base-case analysis.

Regimen Cost Progression-free LYs Overall LYs QALYs Incremental cost per QALY* Incremental cost per LY*
FOLFIRI (control regimen) 30,668 0.795 2.066 0.963
Cetuximab with PAP 39,511 0.944 2.796 1.593 14,049 12,107
Cetuximab without PAP 47,754 0.944 2.796 1.593 27,145 23,393

* Compared to a control regimen.